# Contact Southern Peptide Co — Editorial Desk

> Reach the Southern Peptide Co editorial desk regarding citations, corrections, or research correspondence about our Recovery & Tissue Repair peptide briefing.

Correspondence on citations, corrections, and research updates — the messages this briefing is built to receive.

## Editorial correspondence

Southern Peptide Co welcomes correspondence on the research record: a citation quoted inaccurately, a newly published trial, a regulatory update that changes an approval or WADA-prohibited status, or a peer-reviewed study on GHK-Cu, TB-500, or BPC-157 that should be added to the [references page](/references). This class of correction is the most useful message this desk receives.

The most actionable submissions specify the page in question, the exact passage being corrected, and a supporting reference — a DOI or PubMed identifier where possible — so a proposed change can be verified against its source before it is acted on.

**Editorial mailbox:** editors@southernpeptideco.com

## What this desk cannot do

Southern Peptide Co is a literature briefing, not a clinical service or product vendor, so it cannot advise on or recommend human use of any peptide discussed here, suggest a dose or route of administration for any individual, evaluate whether a cited finding applies to a specific person's situation, or sell, source, or help locate any compound from any supplier. It also cannot advise athletes subject to anti-doping testing, given that two of the three compounds discussed here fall under WADA-prohibited categories.

None of the compounds covered on this site is an approved systemic medicine. Readers seeking medical guidance should consult a licensed clinician in their jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.

---

An independent tissue-repair research briefing: what is documented, what is reported, and what remains unknown — never a prescription.